348 TIL engineered with membrane-bound IL15 (cytoTIL15™) are enriched for tumor-associated antigen reactivity and demonstrate pharmacologically tunable expansion and persistence in the presence of TAA

• Kyle Pedro,
• Alonso Villasmil Ocando,
• Benjamin Primack,
• Meghan Langley,
• Theresa Ross,
• Jeremy Tchaicha,
• Michelle Ols,
• Jan ter Meulen,
• Violet Young,
• Gauri Kulkarni,
• Arman Aksoy,
• Rachel A Burga

Affiliations

Kyle Pedro

2Obsidian Therapeutics, Cambridge, MA, USA

Alonso Villasmil Ocando

2Obsidian Therapeutics, Cambridge, MA, USA

Benjamin Primack

2Obsidian Therapeutics, Cambridge, MA, USA

Meghan Langley

2Obsidian Therapeutics, Cambridge, MA, USA

Theresa Ross

2Obsidian Therapeutics, Cambridge, MA, USA

Jeremy Tchaicha

2Obsidian Therapeutics, Cambridge, MA, USA

Michelle Ols

2Obsidian Therapeutics, Cambridge, MA, USA

Jan ter Meulen

2Obsidian Therapeutics, Cambridge, MA, USA

Violet Young

2Obsidian Therapeutics, Cambridge, MA, USA

Gauri Kulkarni

2Obsidian Therapeutics, Cambridge, MA, USA

Arman Aksoy

2Obsidian Therapeutics, Cambridge, MA, USA

Rachel A Burga

1Obsidian Therapeutics, Waltham, MA, USA